Shenling Baizhu Powder Inhibits Lung Metastasis of Breast Cancer via Regulation of Epithelial-Mesenchymal Transition and Ferroptosis.

IF 0.9 4区医学 Q4 IMMUNOLOGY

Critical Reviews in Immunology Pub Date : 2025-01-01 DOI:10.1615/CritRevImmunol.2025059697

Wei Tian, Junquan Han

{"title":"Shenling Baizhu Powder Inhibits Lung Metastasis of Breast Cancer via Regulation of Epithelial-Mesenchymal Transition and Ferroptosis.","authors":"Wei Tian, Junquan Han","doi":"10.1615/CritRevImmunol.2025059697","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to probe the role of Shenling Baizhu powder (SLBZP) in inhibiting breast cancer (BC) lung metastasis, focusing on epithelial-to-mesenchymal transition (EMT) and ferroptosis.Methods: BC 4T1 cells were treated with low (3.13 µg/mL) and high (12.5 µg/mL) doses of SLBZP. Cell proliferation, migration, and invasion were assessed via CCK-8 and transwell assays. Intracellular reactive oxygen species (ROS), malondialdehyde (MDA), and Fe2+ levels were measured using commercial kits. Western blot was used to detect EMT markers (E-cadherin, N-cadherin, Vimentin). In vivo, Balb/c mice injected with 4T1 cells received SLBZP or cyclophosphamide (CTX). Tumor volume, mass, and lung metastases were recorded. MDA, Fe2+, EMT markers, and ferroptosis-related GPX4 were evaluated in tumor tissues.Results: SLBZP dose-dependently suppressed 4T1 cell proliferation, migration, invasion, and EMT, as indicated by upregulated E-cadherin and downregulated N-cadherin and Vimentin. SLBZP increased cellular ROS, MDA, and Fe2+ levels (P < 0.05). In vivo, SLBZP and CTX significantly reduced tumor burden and lung metastases, elevated MDA, Fe2+, and E-cadherin, and decreased N-cadherin, Vimentin, and GPX4 in tumor tissues (P < 0.05).Conclusion: SLBZP inhibits BC lung metastasis by modulating EMT and ferroptosis, highlighting its therapeutic potential.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":"45 5","pages":"11-18"},"PeriodicalIF":0.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevImmunol.2025059697","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to probe the role of Shenling Baizhu powder (SLBZP) in inhibiting breast cancer (BC) lung metastasis, focusing on epithelial-to-mesenchymal transition (EMT) and ferroptosis.

Methods: BC 4T1 cells were treated with low (3.13 µg/mL) and high (12.5 µg/mL) doses of SLBZP. Cell proliferation, migration, and invasion were assessed via CCK-8 and transwell assays. Intracellular reactive oxygen species (ROS), malondialdehyde (MDA), and Fe2+ levels were measured using commercial kits. Western blot was used to detect EMT markers (E-cadherin, N-cadherin, Vimentin). In vivo, Balb/c mice injected with 4T1 cells received SLBZP or cyclophosphamide (CTX). Tumor volume, mass, and lung metastases were recorded. MDA, Fe2+, EMT markers, and ferroptosis-related GPX4 were evaluated in tumor tissues.

Results: SLBZP dose-dependently suppressed 4T1 cell proliferation, migration, invasion, and EMT, as indicated by upregulated E-cadherin and downregulated N-cadherin and Vimentin. SLBZP increased cellular ROS, MDA, and Fe2+ levels (P < 0.05). In vivo, SLBZP and CTX significantly reduced tumor burden and lung metastases, elevated MDA, Fe2+, and E-cadherin, and decreased N-cadherin, Vimentin, and GPX4 in tumor tissues (P < 0.05).

Conclusion: SLBZP inhibits BC lung metastasis by modulating EMT and ferroptosis, highlighting its therapeutic potential.

查看原文本刊更多论文

参苓白术散通过调节上皮-间质转化和铁下垂抑制乳腺癌肺转移。

目的：探讨参苓白术散（SLBZP）对乳腺癌肺转移的抑制作用，重点探讨其对上皮-间质转化（EMT）和铁下垂的抑制作用。方法：采用低剂量（3.13µg/mL）和高剂量（12.5µg/mL）的SLBZP处理BC 4T1细胞。通过CCK-8和transwell检测细胞增殖、迁移和侵袭。使用商业试剂盒检测细胞内活性氧（ROS）、丙二醛（MDA）和Fe2+水平。Western blot检测EMT标志物（E-cadherin, N-cadherin, Vimentin）。在体内，注射4T1细胞的Balb/c小鼠接受SLBZP或环磷酰胺（CTX）。记录肿瘤的体积、质量和肺转移情况。检测肿瘤组织中MDA、Fe2+、EMT标志物和铁中毒相关GPX4。结果：SLBZP剂量依赖性地抑制4T1细胞的增殖、迁移、侵袭和EMT，表现为E-cadherin上调，N-cadherin和Vimentin下调。SLBZP提高了细胞ROS、MDA、Fe2+水平（P < 0.05）。在体内，SLBZP和CTX显著降低肿瘤负荷和肺转移，升高肿瘤组织中MDA、Fe2+、E-cadherin，降低N-cadherin、Vimentin和GPX4 （P < 0.05）。结论：SLBZP通过调节EMT和铁下垂抑制BC肺转移，显示其治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical Reviews in Immunology 医学-免疫学

CiteScore

2.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Immunology covers a broad spectrum of investigations at the genes, molecular, cellular, organ and system levels to reveal defense mechanisms against pathogens as well as protection against tumors and autoimmune diseases. The great advances in immunology in recent years make this field one of the most dynamic and rapidly growing in medical sciences. Critical ReviewsTM in Immunology (CRI) seeks to present a balanced overview of contemporary adaptive and innate immune responses related to autoimmunity, tumor, microbe, transplantation, neuroimmunology, immune regulation and immunotherapy from basic to translational aspects in health and disease. The articles that appear in CRI are mostly obtained by invitations to active investigators. But the journal will also consider proposals from the scientific community. Interested investigators should send their inquiries to the editor before submitting a manuscript.